Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial

Lenalidomide, bortezomib, and dexamethasone (RVd) followed by autologous stem cell transplantation (ASCT) is standard frontline therapy for transplant-eligible patients with newly diagnosed multiple myeloma (NDMM). The addition of daratumumab (D) to RVd (D-RVd) in transplant-eligible NDMM patients w...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood
Hlavní autoři: Voorhees, Peter M., Kaufman, Jonathan L., Laubach, Jacob, Sborov, Douglas W., Reeves, Brandi, Rodriguez, Cesar, Chari, Ajai, Silbermann, Rebecca, Costa, Luciano J., Anderson, Larry D., Nathwani, Nitya, Shah, Nina, Efebera, Yvonne A., Holstein, Sarah A., Costello, Caitlin, Jakubowiak, Andrzej, Wildes, Tanya M., Orlowski, Robert Z., Shain, Kenneth H., Cowan, Andrew J., Murphy, Sean, Lutska, Yana, Pei, Huiling, Ukropec, Jon, Vermeulen, Jessica, de Boer, Carla, Hoehn, Daniela, Lin, Thomas S., Richardson, Paul G.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2020
Témata:
Clinical Trials and Observations
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7441167/
https://ncbi.nlm.nih.gov/pubmed/32325490
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020005288
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky